Welcome!
Stem Med
Broker's Calls
Monetisation of TalkMed’s stem cell treatment for cancer will have to wait
SINGAPORE (Oct 2): RHB is maintaining its “buy” call on TalkMed with lower 69 cents target price despite seeing huge potential in stem cells as a way of treatment, particularly for cancer.
October 02, 2017